Výsledky vyhledávání - "Abril Verden"

Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors

Autor: Keith B. Hoffman, Mo Dimbil, Brian M. Overstreet, Abril Verden, Robert F. Kyle

Publikováno v: Drug Safety. 41:357-361

The Janus kinase (JAK) inhibitor baricitinib is approved in Europe and Japan for the treatment of rheumatoid arthritis. In April 2017, the US FDA expressed concern about thromboembolic events (deep venous thrombosis [DVT] and pulmonary embolism [PE])

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21fb5b5e89828329f8caca6099519acf
https://doi.org/10.1007/s40264-017-0622-2

Zobrazit plný text záznamu

Amyotrophic Lateral Sclerosis Associated with Statin Use: A Disproportionality Analysis of the FDA's Adverse Event Reporting System

Autor: Beatrice A. Golomb, Alexis K. Messner, Abril Verden, Keith B. Hoffman, Hayley J. Koslik

Publikováno v: Drug safety. 41(4)

Apparent elevations in reporting of amyotrophic lateral sclerosis (ALS)-like conditions associated with statin use have been previously described from data obtained via US and European databases. The aim of this study was to examine US FDA Adverse Ev

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a80bbba1532b8f8559b16e1a46e36c55
https://pubmed.ncbi.nlm.nih.gov/29427042

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání